Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum
Version of Record online: 7 APR 2005
Journal of Neurochemistry
Volume 93, Issue 3, pages 762–765, May 2005
How to Cite
Rassoulpour, A., Wu, H.-Q., Ferrė, S. and Schwarcz, R. (2005), Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum. Journal of Neurochemistry, 93: 762–765. doi: 10.1111/j.1471-4159.2005.03134.x
- Issue online: 7 APR 2005
- Version of Record online: 7 APR 2005
- Received December 7, 2004; revised manuscript received January 19, 2005; accepted January 28, 2005.
- α7 nicotinic acetylcholine receptor;
- basal ganglia;
- glia–neuron interactions;
- neurodegenerative diseases;
Precise regulation of dopaminergic activity is of obvious importance for the physiology and pathology of basal ganglia. We report here that nanomolar concentrations of the astrocyte-derived neuroinhibitory metabolite kynurenic acid (KYNA) potently reduce the extracellular levels of striatal dopamine in unanesthetized rats in vivo. This effect, which is initiated by the KYNA-induced blockade of α7 nicotinic acetylcholine receptors, highlights the functional relevance of glia–neuron interactions in the striatum and indicates that even modest increases in the brain levels of endogenous KYNA are capable of interfering with dopaminergic neurotransmission.